These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1315 related articles for article (PubMed ID: 26504000)

  • 1. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
    Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
    Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.
    Berger LA; Riesenberg H; Bokemeyer C; Atanackovic D
    Lung Cancer; 2013 Jun; 80(3):242-8. PubMed ID: 23453646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
    Klempner SJ; Ou SH
    Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
    Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
    Song Z; Zhang Y
    J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.